跳至主要内容
临床试验/JPRN-UMIN000012791
JPRN-UMIN000012791已完成4 期

Evaluation of the safety and efficacy of tosufloxacin granules for pediatric with bacterial pneumonia, otitis media - Evaluation of the safety and efficacy of tosufloxacin granules for pediatric with bacterial pneumonia, otitis media

Toyama Chemical Co., Ltd.0 个研究点目标入组 700 人开始时间: 2014年1月8日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
700

研究概览

简要总结

There were a total of 760 patients included in the compliance analysis, 759 in the safety analysis, 688 in the efficacy analysis and 20 in the bacteriological efficacy analysis. The incidence of adverse drug reactions (ADRs) was 2.77% (21/759), and the major ADRs were gastrointestinal disorders including diarrhea in 16 patients (2.11%). Nausea vomiting and joint disorders were intensively investigated. Vomiting was reported in 8 patients (1.05%), which was not clinically significant. No joint disorders were reported. The overall efficacy rate was 98.1% (675/688). The efficacy rate by the type of infection was 100% (145/145) for bacterial pneumonia and 97.7% (506/518) for otitis media. The eradication rates of Streptococcus pneumoniae and Haemophilus influenzae which are major causative or organisms in pediatric infections of pneumonia and otitis media were 7/8 and 93.3% (14/15), respectively. The compliance was good in 87.5% of the patients (665/760).

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 15years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who have a history of hypersensitivity to tosufloxacin Patients who are pregnant or possibly pregnant

研究者

相似试验

Evaluation of the safety and efficacy of... | 临床试验